Michelle Casey

10.6k total citations · 2 hit papers
58 papers, 3.5k citations indexed

About

Michelle Casey is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Michelle Casey has authored 58 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Michelle Casey's work include HER2/EGFR in Cancer Research (9 papers), Cancer Genomics and Diagnostics (9 papers) and Renal cell carcinoma treatment (8 papers). Michelle Casey is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Cancer Genomics and Diagnostics (9 papers) and Renal cell carcinoma treatment (8 papers). Michelle Casey collaborates with scholars based in United States, United Kingdom and France. Michelle Casey's co-authors include George W. Sledge, Keith T. Flaherty, Dirk Schadendorf, Harold J. Burstein, Catherine Ellis, Kimberly Blackwell, James Larkin, Claus Garbe, Svetislava J. Vukelja and Paul Nathan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Michelle Casey

54 papers receiving 3.5k citations

Hit Papers

Improved survival with MEK Inhibition in BRAF-mutated mel... 2010 2026 2015 2020 2012 2010 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
    2012 1.1k citations Keith T. Flaherty, Peter Hersey et al. profile →
  2. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
    2010 701 citations Kimberly Blackwell, Harold J. Burstein et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michelle Casey United States 21 2.2k 1.6k 937 690 516 58 3.5k
Marzia Del Re Italy 34 1.6k 0.7× 1.5k 1.0× 1.6k 1.7× 1.3k 1.9× 394 0.8× 167 3.9k
Francesco Caponigro Italy 28 2.3k 1.0× 2.0k 1.3× 1.2k 1.3× 552 0.8× 399 0.8× 101 4.6k
Sherry X. Yang United States 21 1.5k 0.6× 1.8k 1.1× 372 0.4× 904 1.3× 299 0.6× 54 3.2k
Laleh Amiri‐Kordestani United States 28 1.9k 0.9× 713 0.4× 1.0k 1.1× 558 0.8× 497 1.0× 89 3.1k
Antoinette R. Tan United States 36 4.0k 1.8× 1.8k 1.1× 1.5k 1.6× 999 1.4× 581 1.1× 140 5.4k
Giulio Francia United States 31 1.5k 0.7× 1.5k 1.0× 540 0.6× 849 1.2× 257 0.5× 69 3.2k
Julia A. Beaver United States 39 2.7k 1.2× 1.1k 0.7× 1.5k 1.6× 1.1k 1.6× 432 0.8× 131 4.8k
David Chen United States 25 1.4k 0.6× 1.4k 0.9× 1.5k 1.6× 877 1.3× 189 0.4× 75 3.6k
Paolo Tarantino Italy 28 2.3k 1.0× 632 0.4× 826 0.9× 777 1.1× 1000 1.9× 128 3.2k
Misako Nagasaka United States 31 1.9k 0.9× 1.2k 0.8× 1.8k 1.9× 646 0.9× 253 0.5× 205 3.2k

Countries citing papers authored by Michelle Casey

Since Specialization
Citations

This map shows the geographic impact of Michelle Casey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle Casey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle Casey more than expected).

Fields of papers citing papers by Michelle Casey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle Casey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle Casey. The network helps show where Michelle Casey may publish in the future.

Co-authorship network of co-authors of Michelle Casey

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle Casey. A scholar is included among the top collaborators of Michelle Casey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle Casey. Michelle Casey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McDonnell, Thomas, L.J. Cussen, Michelle Casey, et al.. (2025). Sex Hormone Abnormalities Disrupt Circulating Alpha-1 Antitrypsin. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A3471–A3471.
2.
Gogoi, Debananda, Claudie Gabillard-Lefort, Sarfraz Ahmed, et al.. (2025). CFTR modulator therapy impacts neutrophil CD39 expression in cystic fibrosis. American Journal of Respiratory Cell and Molecular Biology. 74(3). 403–406.
3.
Siegel, Jonathan, et al.. (2024). Time‐to‐event estimands and loss to follow‐up in oncology in light of the estimands guidance. Pharmaceutical Statistics. 23(5). 709–727. 5 indexed citations
4.
Casey, Michelle, Claudie Gabillard-Lefort, Oisín F. McElvaney, et al.. (2023). Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis. Thorax. 78(8). 835–839. 56 indexed citations
5.
Gabillard-Lefort, Claudie, Michelle Casey, Fiona Boland, et al.. (2022). Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 205(7). 783–794. 33 indexed citations
6.
White, Michelle M., Debananda Gogoi, David A. Bergin, et al.. (2022). Alpha-1 Antitrypsin Therapy Modifies Neutrophil Adhesion in Patients with Obstructive Lung Disease. American Journal of Respiratory Cell and Molecular Biology. 67(1). 76–88. 7 indexed citations
7.
Williamson, Michael, et al.. (2021). Current evidence on the effect of highly effective CFTR modulation on interleukin-8 in cystic fibrosis. Expert Review of Respiratory Medicine. 16(1). 43–56. 5 indexed citations
8.
Toomey, Sinéad, Stephen F. Madden, Michelle Casey, et al.. (2020). Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19). Thorax. 76(1). 86–88. 57 indexed citations
9.
George, Daniel J., Jean-François Martini, Michael Staehler, et al.. (2018). Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. Clinical Cancer Research. 25(4). 1165–1173. 18 indexed citations
10.
Gross‐Goupil, Marine, Tae‐Geon Kwon, Masatoshi Eto, et al.. (2018). Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Annals of Oncology. 29(12). 2371–2378. 176 indexed citations
11.
George, Daniel J., Allan J. Pantuck, Robert A. Figlin, et al.. (2018). Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial. Annals of Oncology. 29. viii312–viii312. 4 indexed citations
12.
Santiago-Walker, Ademi, Robert Gagnon, Jolly Mazumdar, et al.. (2015). Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clinical Cancer Research. 22(3). 567–574. 158 indexed citations
13.
Kang, Yoon‐Koo, Thomas Yau, Ho Yeong Lim, et al.. (2015). Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Annals of Oncology. 26(12). 2457–2463. 78 indexed citations
14.
Ahmed, Farid, Paul Vos, James N. Atkins, et al.. (2012). Diagnostic microRNA markers to screen for sporadic human colon cancer in blood.. PubMed. 9(4). 179–92. 46 indexed citations
15.
16.
17.
Blackwell, Kimberly, Harold J. Burstein, Anna Maria Storniolo, et al.. (2010). Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer. Journal of Clinical Oncology. 28(7). 1124–1130. 701 indexed citations breakdown →
18.
Moser, Virginia C., et al.. (2005). Neurotoxicological and Statistical Analyses of a Mixture of Five Organophosphorus Pesticides Using a Ray Design. Toxicological Sciences. 86(1). 101–115. 53 indexed citations
19.
Gennings, Chris, et al.. (2004). Analysis of functional effects of a mixture of five pesticides using a ray design. Environmental Toxicology and Pharmacology. 18(2). 115–125. 19 indexed citations
20.
Casey, Michelle, et al.. (2004). Ds-optimal designs for studying combinations of chemicals using multiple fixed-ratio ray experiments. Environmetrics. 16(2). 129–147. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marzia Del Re Breakdown of academic impact, for papers by Francesco Caponigro Breakdown of academic impact, for papers by Sherry X. Yang Breakdown of academic impact, for papers by Laleh Amiri‐Kordestani Breakdown of academic impact, for papers by Antoinette R. Tan Breakdown of academic impact, for papers by Giulio Francia Breakdown of academic impact, for papers by Julia A. Beaver Breakdown of academic impact, for papers by David Chen Breakdown of academic impact, for papers by Paolo Tarantino Breakdown of academic impact, for papers by Misako Nagasaka
Rankless by CCL
2026